Reading the tape
NASDAQ: TVTX
Travere Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$4.28B
52w High
$48.60
52w Low
$13.88
P/E
-92.34
Volume
980.00K
Outstanding Shares
92.37M
Price vs Fundamentals
Why The Stock Is Moving
Optimism is getting priced inModerate confidence
1Y Price: 109.76%Revenue (TTM): 96.03%FCF (TTM): 119.59%P/S: 95th pct
What changed
The stock rose 109.76% over the last year. Revenue grew 96.03% over the trailing twelve months. Operating margin moved from -82.85% to -10.58%. Free cash flow grew 119.59% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/S range (95th percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at -10.58% — continued expansion would be needed to justify the premium. Revenue growth of 96.03% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Company profile
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases.
CEOEric Dube
SectorHealthcare
IndustryBiotechnology
Employees385
IPO dateNov 8, 2012
Valuation
Forward P/E—
EV/EBITDA164.03
Enterprise value$3.64B
Stock splits
Nov 2, 2012↓ Reverse
Every 9 shares became 1
Jul 2, 2009↓ Reverse
Every 100 shares became 1
Profitability & growth
Revenue growth55.63%
Gross margin71.84%▼11.55%vs FY2024
Operating margin-10.58%▲90.78%vs FY2024
ROE-43.77%▲91.96%vs FY2024
Analyst consensus
RatingBuy
Target price$51.50▲11.06%
15
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 5, 2026
Q3 FY26 · EPS est -$0.06 · Revenue est $159.51M
View